Surrozen (SRZN) Cash from Operations (2020 - 2026)
Surrozen (SRZN) recorded quarterly Cash from Operations of 12495000.0 in Q1 2026, down 113.81% quarter-over-quarter from 5844000.0 in Q4 2025, and down 34.35% on a YoY basis from 19034152.33 in Q1 2025.
Surrozen (SRZN) Cash from Operations (2020 - 2026) Analysis & Trends
Surrozen's Cash from Operations history runs 7 years deep, the most recent figure standing at 12495000.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 34.35% year-over-year to 12495000.0; the TTM figure through Mar 2026 stood at 33439000.0 (down 83.73% YoY), while the FY2025 annual figure was 30244000.0, down 71.84% from the prior year.
- Cash from Operations was 12495000.0 for Q1 2026 at Surrozen, down from 5844000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 3509000.0 in Q4 2024 to a low of 18400000.0 in Q1 2022.
- Historically, Cash from Operations has averaged 8519941.18 across 5 years, with a median of 8749000.0 in 2023.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations sank 4462.5% in 2023, then surged 148.07% in 2024.
- A 5-year view of Cash from Operations shows it stood at 160000.0 in 2022, then tumbled by 4462.5% to 7300000.0 in 2023, then soared by 148.07% to 3509000.0 in 2024, then plunged by 266.54% to 5844000.0 in 2025, then slumped by 113.81% to 12495000.0 in 2026.
- The last three Cash from Operations figures came in at 12495000.0 (Q1 2026), 5844000.0 (Q4 2025), and 9000000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - | -12.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.50 Mn |
| Mar 31, 2026 | -12.50 Mn |
| Dec 31, 2025 | -5.84 Mn |
| Dec 31, 2025 | -5.84 Mn |
| Sep 30, 2025 | -9.00 Mn |
| Sep 30, 2025 | -9.00 Mn |
| Jun 30, 2025 | -6.10 Mn |
| Jun 30, 2025 | -6.10 Mn |
| Mar 31, 2025 | -9.30 Mn |
| Mar 31, 2025 | -9.30 Mn |
| Dec 31, 2024 | 3.51 Mn |
| Dec 31, 2024 | 3.51 Mn |
| Sep 30, 2024 | -6.75 Mn |
| Sep 30, 2024 | -6.75 Mn |
| Jun 30, 2024 | -5.66 Mn |
| Jun 30, 2024 | -5.66 Mn |
| Mar 31, 2024 | -8.70 Mn |
| Mar 31, 2024 | -8.70 Mn |
| Dec 31, 2023 | -7.30 Mn |
| Dec 31, 2023 | -7.30 Mn |